The KITLG Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population designed to disrupt KITLG in the A-549 human lung adenocarcinoma epithelial line. This loss-of-function model targets the gene encoding stem cell factor (SCF), the ligand for KIT receptor tyrosine kinase (CD117). The polyclonal format provides a robust, heterogeneous knockout pool, minimizing clonal artifacts while enabling population-level functional studies.
The A-549 cell line, derived from a human lung adenocarcinoma, is a classic epithelial model in cancer biology. It retains wild-type KRAS and exhibits adherent growth, faithfully recapitulating key signaling features of non-small cell lung cancer. This background is ideal for interrogating KITLG-dependent pathways implicated in tumor cell proliferation, survival, and migration.
KITLG (SCF) binds to and activates the KIT receptor tyrosine kinase (CD117), triggering receptor dimerization and autophosphorylation. This initiates signaling through PI3K/AKT, Ras/MAPK (ERK), and JAK/STAT cascades. KITLG expression is regulated by transcription factors MITF, SOX10, PAX3, and HIF-1??, and is modulated by pro-inflammatory cytokines. The pathway also interfaces with FLT3, PDGFR, and CD34, which can modulate signal intensity. Downstream, activated AKT, ERK, and STAT proteins mediate proliferation, survival, and differentiation, while SRC family kinases further propagate signals. In A-549 cells, CRISPR/Cas9-mediated disruption of KITLG abolishes ligand-dependent KIT activation, impairing phosphorylation of these effectors and attenuating tumorigenic phenotypes.
In A-549 lung adenocarcinoma cells, the KITLG-KIT axis contributes to malignant phenotypes, including enhanced proliferation and migration. KITLG knockout provides a specific tool to dissect autocrine or paracrine SCF signaling loops and to evaluate the ligand??s role in tumor maintenance. This model also offers translational insights for diseases linked to KIT pathway dysregulation, such as gastrointestinal stromal tumors and mastocytosis.
Applications include western blotting for KITLG, phospho-KIT, AKT, and ERK; proliferation (MTT, BrdU) and migration/invasion assays; flow cytometric apoptosis analysis; and RNA-seq transcriptomics. RT-qPCR for KITLG and KIT mRNA and phospho-proteomic workflows further enable detailed signaling interrogation. The polyclonal knockout population supports reproducible, population-level readouts in drug target validation and cancer signaling studies. For more information, please contact Ascent Research.
